Article

Study examines risk factors for endophthalmitis after cataract surgery

Author(s):

According to investigators, the elevated risk is associated with cataract type, case complexity, and history of DME/PDR.

A team of investigators that included Michael H. Goldstein, MD, president of Ocular Therapeutix Inc., conducted a large retrospective analysis to identify the risk factors for endophthalmitis after cataract surgery.

The study used the IRIS Registry and reported that complex cataract procedures, the performance of simultaneous vitreous procedures, a history of diabetic macular edema or proliferative diabetic retinopathy, male sex, and certain cataract types were associated with significantly higher rates of endophthalmitis.

The investigators also determined if use of the ReSure Sealant impacted the incidence rate of endophthalmitis either way. This hydrogel sealant creates an in situ temporary soft surface barrier to prevent wound leaks from clear corneal incisions up to 3.5 mm in size following cataract surgery.

The investigators compared the incidence of endophthalmitis within 30 days of any cataract procedures performed with and without the ReSure Sealant and the incidence of endophthalmitis within 30 days after any cataract surgery performed in the US.

This study included patients who underwent cataract surgery from January 1, 2016, to December 1, 2019. All patients underwent phacoemulsification with intraocular lens implantation and had completed 1 or more visits within 30 days postoperatively.

Data from more than 6,700,000 eyes (4.1 million patients; 58.9% women; mean age, 70.91 years) were included. More than 3.5 million eyes underwent surgery at practices in which the ReSure Sealant was available.

About 93% of cases were routine and the remainder were considered complex. Two-thirds of the cataracts were the nuclear sclerotic type, and the rest were cortical, posterior subcapsular, congenital, and traumatic. Glaucoma procedures were performed concurrently in about 3.5% of cases and vitreous procedures in about 0.5% of cases. Slightly more than 20% of patients had a history of diabetes.

The overall incidence of endophthalmitis was 0.633 case per 1000 surgeries.

The incidence of endophthalmitis was significantly higher after complex procedure compared to routine procedures, ie, 1.148 vs. 0.592 case per 1000 surgeries, respectively (p < 0.0001).

Based on the use or no use of the ReSure Sealant, no significant difference was found in the incidence of endophthalmitis, i.e., 0.609 vs. 0.660, respectively.

The specific clinical risk factors that the data analysis identified in association with higher incidence rates of endophthalmitis were complex cataract procedures (odds ratio [OR], 1.67); concurrent vitreous procedures (OR, 4.32); traumatic (OR, 4.84), nuclear sclerotic (OR, 1.18), and posterior subcapsular (OR, 1.21) cataracts; and a history of proliferative diabetic retinopathy (OR, 1.53) or diabetic macular edema (OR, 2.04). Male sex (OR, 1.19) and multiethnicity (OR, 2.60) also were significant risk factors. All comparisons were significant (p < 0.0001).

“These results provide risk factors for endophthalmitis after cataract surgery from 2016 to 2019 and can identify patients at high risk of developing endophthalmitis after cataract surgery,” Goldstein concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.